Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Fiche publication
Date publication
mars 2024
Journal
Breast cancer research and treatment
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Dr JOUANNAUD Christelle
Tous les auteurs :
Ginzac A, Molnar I, Durando X, Motte Rouge T, Petit T, D'hondt V, Campone M, Bonichon-Lamichhane N, Venat Bouvet L, Levy C, Augereau P, Pistilli B, Arsene O, Jouannaud C, Nguyen S, Cayre A, Tixier L, Mahier Ait Oukhatar C, Nabholtz JM, Penault-Llorca F, Mouret-Reynier MA
Lien Pubmed
Résumé
Previous studies have reported the benefit of dual HER2-targeting combined to neoadjuvant chemotherapy in HER2-amplified breast cancer (HER2 + BC). Moreover, besides the cardiac toxicity following their association to Trastuzumab, anthracyclines chemotherapy may not profit all patients. The NeoTOP study was designed to evaluate the complementary action of Trastuzumab and Pertuzumab, and the relevance of an anthracycline-based regimen according to TOP2A amplification status.
Mots clés
HER2-positive breast Cancer (HER2 + BC), Pathological complete response (pCR), Pertuzumab, TOP2A, Trastuzumab
Référence
Breast Cancer Res Treat. 2024 03 7;: